Daiichi Sankyo, Eli Lilly: New drug still on track

(AP) -- Japanese drug maker Daiichi Sankyo Co. and U.S. partner Eli Lilly & Co. sought to reassure investors Friday that a highly anticipated blood thinner remains on track for approval, despite escalating concerns of further delays by federal health regulators.

Read the whole article on Physorg

More from Physorg